HAIXI PHARMA (02637)
| Auditor | From | To | Release Date / Document Links | Reason for Change |
|---|---|---|---|---|
| RSM (China) | 04-Aug-26 | |||
| Deloitte | 17-Oct-25 | 04-Aug-26 | SUPPLEMENTAL ANNOUNCEMENT - The Company wishes to clarify that it was the receipt, within a relatively short and concentrated period around and after the last annual general meeting dated 27 May 2026, of successive and specific requests from PRC governmental authorities and PRC commercial banks for audit report prepared under CASBE that prompted the Company to reassess the appropriateness of its existing financial reporting framework. | |
| Deloitte | 15-Jul-26 | The Company decided to align the preparation of its financial reports in accordance with China Accounting Standards for Business Enterprises (CASBE) starting from the interim financial report for the period ended 30 June 2026. Since RSM China CPA LLP is a PRC external auditor is qualified to provide audit services to mainland China-incorporated issuers listed in Hong Kong, the Company proposed to terminate the engagement of Deloitte Touche Tohmatsu and appoint RSM China CPA LLP as its external auditor. |